Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability

Abstract excerpt

<h4>ABSTRACT</h4> Lassa virus (LASV) is responsible for 100,000-300,000 zoonotic infections annually and poses a threat to public health. Development of antibody-based therapeutics or vaccines has been challenging because neutralizing antibodies – even among Lassa hemorrhagic fever survivors – are generally of low titer, and the target of neutralizing antibodies, the trimeric glycoprotein complex (GPC), a type 1-...

Topics

Open a Topic to create a Post that cites this publication.

• Antibodies, Neutralizing
• Bacteriophages and microbial interactions
• Camelus
• env Gene Products, Human Immunodeficiency Virus
• Monoclonal and Polyclonal Antibodies Research
• SARS-CoV-2 and COVID-19 Research
• Single-Domain Antibodies
• Viral Infections and Outbreaks Research

Identifiers and source

Literature Corpus work

44810f28-fc47-5a2e-8adc-7fc1ce1b91cf

DOI

10.1101/2022.04.21.488985